Sign in Subscribe
College of American Pathologists

Revised 2018 Evidence-Based Guideline on Molecular Testing for Lung Cancer Now Open for Public Comment

Strategic Insights

— 1 min read

The College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology have announced the open comment period for the revised 2018 evidence-based guideline on molecular testing for lung cancer. The guideline updates aim to provide state-of-the-art molecular testing recommendations for lung cancer professionals. The revised guideline addresses next-generation sequencing and expanded biomarker testing for patients with non-squamous non-small cell lung carcinoma participating in other clinical trials.

Key Takeaways:

  • The open comment period for the revised 2018 evidence-based guideline on molecular testing for lung cancer is from August 14 to September 12, 2024.
  • The guideline revisions aim to provide state-of-the-art molecular testing recommendations for lung cancer professionals, considering evidence from an unbiased review of published experimental literature since 2018.
  • The final recommendations will be approved and jointly published after consideration of the public comments, further panel discussion, and complete evidence analysis.
  • The revised guideline addresses next-generation sequencing and expanded biomarker testing for patients with non-squamous non-small cell lung carcinoma participating in other clinical trials.
  • The expert panel formulated new draft recommendations addressing key questions, such as whether biomarker testing improves treatment response rates and survival rates in patients with NSCLC being considered for molecularly targeted therapies.
  • The revised guideline is expected to be a valuable resource for pathologists, oncologists, patient advocacy groups, and cancer and molecular diagnostic laboratory professionals.
  • The organizations will develop clinical tools and resources for pathologists and oncologists that summarize the findings and recommendations, as well as a patient guide for further understanding.

Statistics:

  • The open comment period for the revised 2018 evidence-based guideline on molecular testing for lung cancer is 30 days, from August 14 to September 12, 2024.
  • Members of the expert panel, including guideline update co-chairs Sinchita Roy-Chowdhuri, MD, PhD, FCAP, Sanja Dacic, MD, PhD, FCAP, and Neal I. Lindeman, MD, formulated new draft recommendations addressing 9 key questions.
  • The revised guideline is an update and extension of the 2013 and 2018 practice guidelines that established evidence-based best practices for molecular biomarker testing for patients diagnosed with lung adenocarcinoma.

Sources:

  • International Association for the Study of Lung Cancer
  • College of American Pathologists
  • Association for Molecular Pathology

Read more